Day: January 18, 2021

SPLK – ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Splunk Inc. Investors of Important Deadline in Securities Class Action – SPLK

NEW YORK, Jan. 18, 2021 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Splunk Inc. (NASDAQ: SPLK) between October 21, 2020 and December 2, 2020, inclusive (the “Class Period”), of the important February 2, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Splunk investors under the federal securities laws.

To join the Splunk class action, go to http://www.rosenlegal.com/cases-register-2000.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Splunk was not closing deals with its largest customers in the third fiscal quarter of 2021; (2) Splunk was not hitting the financial targets it had previously announced; and (3) as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 2, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-2000.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor
New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

SOURCE Rosen Law Firm, P.A.

Related Links

www.rosenlegal.com

PEN – Rosen, A Leading and Top Ranked Law Firm, Continues to Investigate Securities Claims Against Penumbra, Inc. – PEN

New York, New York–(Newsfile Corp. – January 18, 2021) – Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Penumbra, Inc. (NYSE: PEN) resulting from allegations that Penumbra may have issued materially misleading business information to the investing public.

On November 10, 2020, Quintessential Capital Management released research report on the Company entitled “Penumbra and its ‘Killer Catheter’: A tale of corporate greed and seemingly blatant disregard for patients’ lives[.]”

On December 8, 2020, Quintessential Capital Management released a follow-up research report entitled “Is Penumbra’s core scientific research authored by a fake person?: The incredible story of Penumbra’s Dr. Antik Bose[.]” The follow-up report alleged that some of the Company’s scientific research pieces appear to have been incorrectly attributed or even authored by a fake individual. On this news, Penumbra’s share price fell $19.95 per share, or almost 9%, to close at $204.07 per share on December 8, 2020.

On December 15, 2020, after the markets closed, Penumbra announced that it was “voluntarily recalling all configurations” of its JET 7 Xtra Flex Reperfusion Catheter “because the catheter may become susceptible to distal tip damage during use.”

Following the recall, Penumbra’s shares fell $13.84 per share, or 7.3%, to close at $174.98 on December 16, 2020.

Rosen Law Firm is preparing a securities lawsuit on behalf of Penumbra shareholders. If you purchased securities of Penumbra please visit the firm’s website at http://www.rosenlegal.com/cases-register-2003.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72310

info

GTT – ROSEN, A TOP RANKED LAW FIRM, Reminds GTT Communications, Inc. Investors of Important Deadline in Securities Class Action First Filed by Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm – GTT

NEW YORK, Jan. 18, 2021 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of GTT Communications, Inc. (NYSE: GTT) between May 5, 2016 and November 9, 2020, inclusive (the “Class Period”), of the important March 15, 2021 deadline in the securities class action first filed by the firm. The lawsuit seeks to recover damages for GTT investors under the federal securities laws.

To join the GTT class action, go http://www.rosenlegal.com/cases-register-1927.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company’s internal controls suffered from issues related to the recording and reporting of Cost of Telecommunications Services; (2) the Company’s previously reported Cost of Telecommunications was inaccurate or accounted for unsupported adjustments; (3) inadequate internal controls would result in delays in the Company’s 10-Q quarterly reports; and (4) as a result of the foregoing, Defendants’ public statements were materially false and/or misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 15, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1927.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.

      Phillip Kim, Esq.

      The Rosen Law Firm, P.A.

      275 Madison Avenue, 40th Floor

      New York, NY  10016

      Tel: (212) 686-1060

      Toll Free: (866) 767-3653

      Fax: (212) 202-3827

      [email protected]

      [email protected]

      [email protected] 

      www.rosenlegal.com

SOURCE Rosen Law Firm, P.A.

Related Links

www.rosenlegal.com

CRM – Salesforce leads $15M investment round in Indian HR tech platform Darwinbox

Darwinbox, which operates a cloud-based human resource management platform, has raised $15 million in a new financing round as the Indian startup looks to further expand in the country and Southeast Asian markets.

The new round — a Series C — for the Hyderabad-headquartered startup was led by Salesforce Ventures, the venture arm of the American enterprise giant. This is Salesforce Ventures’ one of rare investments in Asia. Existing investors including Lightspeed India and Sequoia Capital India also participated in the round, which brings the five-year old startup’s raise to-date to about $35 million.

Over 500 firms including — Tokopedia, Indorama, JG Summit Group, Zilingo, Zalora, Fave, Adani, Mahindra, Kotak, TVS, National Stock Exchange, Ujjivan Small Finance Bank, Dr.Reddy’s, Nivea, Puma, Swiggy, Bigbasket — use Darwinbox’s HR platform to provide more than a million employees of theirs with a range of features in 60 nations, up from about 200 firms across 50 nations in late 2019, said Chaitanya Peddi, co-founder of Darwinbox, in an interview with TechCrunch.

Peddi said the startup has always looked up to Salesforce for inspiration, and investment from the enterprise giant is “nothing sort of a child receiving validation from their father,” he said.

The fundraise caps the most successful year for the startup that started with uncertainty as the coronavirus spread across Asian nations. The startup initially took a hit as its customers scrambled to navigate through the global pandemic, but the last two quarters have been its best to date, said Peddi.

Overall, the startup’s revenue has ballooned by 300% since September 2019, when it last raised money, he said. “In HR tech and SaaS space, we are now only behind SAP and Oracle in India in terms of revenue,” he said.

Dev Khare, a partner at Lightspeed India, an early backer of the startup, said that Darwinbox has become the preferred human capital management solution for Asian conglomerates, governments, and high-growth businesses and multi-national corporations operating in Asia as they witness digital transformation.

Image Credits: Darwinbox

Darwinbox’s platform is built to take care of the entire “hiring to retiring” cycle needs of employees. It handles onboarding of new hires, keeps a tab on their performance, monitors attrition rate, and provides an ongoing feedback loop.

It also provides its customers with a social network for their employees to remain connected with one another and an AI assistant to apply for a leave or set up meetings with quick voice commands from their phones.

Peddi said the startup will deploy the fresh capital to expand to several more countries, especially in more emerging markets in the Middle East Asia and Africa, and broaden its offerings. “We will be leveraging the power of our platform to do a lot more. We are a product-led firm and our focus will remain on innovation in that space,” he said. The startup is also open to exploring opportunities to acquire smaller firms for inorganic growth, he said.

“India is home to one of the world’s youngest population, and by 2050, it is expected to account for over 18% of the global working age population,” said Arundhati Bhattacharya, Chairperson and CEO, Salesforce India, in a statement. “This makes technology platforms like Darwinbox, that focuses on workforces, incredibly important. I’m proud that Salesforce is supporting Darwinbox on their journey as they continue to grow and innovate in this space.”

Alex Kayyal, partner and head of international at Salesforce Ventures, told TechCrunch in an interview that the firm helps its partners in a number of ways, including exposing them to the firm’s customers, executives and their networks, and helping startups scale their business.

“We have one of the most innovative and disruptive customer bases that are looking for cloud solutions and digital transformation. So the opportunity to expose companies like Darwinbox to our customer base is something we get really excited about,” said Kayyal. Salesforce Ventures is exploring more investment opportunities in India, he said.

PEN – PENUMBRA SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Penumbra, Inc. – PEN

NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 16, 2021 to file lead plaintiff applications in a securities class action lawsuit against Penumbra, Inc. (NYSE: PEN), if they purchased the Company’s shares between August 3, 2020 and December 15, 2020, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

What You May Do

If you purchased shares of Penumbra and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nyse-pen/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 16, 2021.

About the Lawsuit

Penumbra and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

Following a series of prior negative disclosures, on December 15, 2020, post-market, the Company disclosed that it was issuing an “urgent” and “voluntary” recall of its Jet 7 Xtra Flex product because the catheter “may become susceptible to distal tip damage during use” potentially leading to injury or death.

On this news, the price of Penumbra’s shares declined, damaging investors.

The case is Williams v. Penumbra, et al., 21-cv-420.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

BNGO – Day Five of Bionano's Next-Generation Cytogenomics Symposium: Saphyr Identifies Structural Variants that May Predispose to Severe COVID-19 Illness

COVID-19 Host Genome Structural Variant (SV) Consortium used Saphyr to identify SVs in severe COVID-19 patients that affect genes involved in immunity, airway mucous, and viral replicationSVs found by several investigators point to a central role for disease severity of the interferon response pathwayConsortium has added investigators from Augusta University, Boston Children’s Hospital, New York Genome Center, Radboud University, Rockefeller University, UC San Diego, Virginia Commonwealth University, and two dozen other institutes from around the worldSAN DIEGO, Jan. 18, 2021 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the last day of its five-day Next-Generation Cytogenomics Symposium featured presentations by members of the COVID-19 Host Genome Structural Variant (SV) Consortium using the Saphyr® system for optical genome mapping (OGM) to analyze the genomes of patients with severe COVID-19 disease. The presentations by scientists and clinicians from leading hospitals and research institutions in Europe and the US showed that Saphyr was able to detect structural variants that may predispose to severe or mild COVID-19 disease, which had not been identified previously by large studies using next-generation sequencing (NGS) or array-based methods to analyze genomic variation.
Dr. Alex Hoischen, Radboud University, discussed his published results on genomic variants found in families with severe COVID-19. In two families with severely ill brothers, mutations were found in the Toll Like Receptor 7 gene (TLR7), which affects the production of interferons, signaling molecules used to control the immune response. Several other studies have since made similar findings in other genes of the TLR family. Dr. Hoischen discussed how individual patients each may carry individually rare variants, that are collectively common and point to important pathways involved in the disease. His interest in the consortium is based on his understanding that larger SVs have a greater chance to be rare and disruptive, and genome-wide studies have lacked so far in their assessment.Dr. Erich Jarvis, Howard Hughes Medical Institute investigator, professor at The Rockefeller University and head of the Vertebrate Genome Project (VGP), discussed an interesting difference between hospitalized patients and controls where the severely ill show more variation in a part of the Interferon Alpha and Beta Receptor Subunit 1 gene, a key part of the interferon pathway that regulates immune response. Dr. Jarvis is using Saphyr and the pipeline he developed for the VGP to build reference-quality genomes of patients and controls and will compare them with each other and with animal species that are sensitive to infection with SARS-CoV-2 or not, as previously reported.Dr. Ravindra Kolhe, Vice-Chairman of Pathology at the Medical College of Georgia at Augusta University and founder of the COVID-19 Host Genome SV Consortium explained that he founded the consortium because COVID-19 shows a split mortality where a very large number of people get infected, but only a small percentage of those get sick or die. Mortalities are associated with diabetes, hypertension and a history of heart failure, yet independent of that a seemingly random group of patients get extremely ill. Since other studies looking at host genetics use NGS or single nucleotide polymorphism (SNP) arrays that are ill suited to analyze SVs, the consortium focuses on the use of OGM to detect the larger genomic variants most likely to make the largest impact.Dr. Kolhe presented the previously announced finding from the consortium on 37 ICU-admitted, severely ill COVID-19 patients whose genomes were analyzed using Saphyr. In several severely ill patients Saphyr detected structural variants affecting important immune genes. In another patient Saphyr found a duplication of the STK26 gene, which reduces the production of interferon likely leading to reduced viral clearance and increasing the disease severity. When other severely ill patients were compared with asymptomatic COVID-19 patients, the same STK26 gene was found to be significantly more active in all the sick patients, making it a possible biomarker for disease severity. OGM identified many more variants in the severely ill patients affecting genes controlling immunity, airway mucous, and viral replication. Dr. Kolhe stated that his team wants to use structural variants identified with Saphyr to design preventative measures for those people whose genomes show them to be the most vulnerable and develop a biomarker panel that can be run at the time of patient admission, to make sure that appropriate measures are taken based on the genetic makeup and patients get the treatment they need as early as possible. In order to do so, the consortium has announced plans to analyze 1000 genomes with Saphyr allowing them to determine with high confidence which SV are involved in disease susceptibility and severity.Siavash Raisi, Dr. Vineet Bafna’s laboratory at UCSD presented on FaNDOM, an algorithm they developed that is used by the consortium to quickly and efficiently verify the structural variants identified by the Saphyr system. It was able to provide an independent confirmation of all of the variants identified by Saphyr using Bionano Access and Solve software and reported in the consortium publication. Dr. Silviu-Alin Bacanu, Virginia Commonwealth University described how existing resources and other host genome studies can be used to prioritize genes and structural variants identified with Saphyr. He described several studies including the genome-wide association studies on COVID-19 host genetics and the UK Biobank which has collected genomic data on more than 250,000 individuals. Although these large studies are unable to identify important large variants directly, their data can help prioritize variants detected by OGM based on whether they affect genes or pathways which these larger studies have identified as possible correlated with disease severity and outcome.Dr. Alan Beggs and Dr. Catherine Brownstein, Boston Children’s Hospital (BCH) discussed their previously announced study on the genomes of patients with Multisystem Inflammatory Syndrome in Children (MIS-C), a severe inflammatory attack of multiple organs weeks after COVID-19 infection in children with an average age of 8 years old. BCH has reported 67 cases of hospitalized MIS-C, and the Children’s Rare Disease Cohort Initiative has banked their specimens. Drs. Beggs and Brownstein are enrolling 50 patients each with MIS-C, severe COVID-19, and asymptomatic or mildly affected patients and will compare their genomes using OGM with Saphyr and with NGS.Dr. Michael Zody, New York Genome Center (NYGC) presented on the use of NGS on patients also analyzed with Saphyr. The NYGC has an active research project to sequence both the viral and the patient genomes using NGS. Their study is focused on patients with severe COVID-19 without prior high-risk diseases and on MIS-C cases, and in a collaboration with Dr. Jean-Laurent Casanova has found rare defects in immunity that affect the disease severity by altering the interferon response in patients. By combining the NGS data collected by NYGC with the OGM data from the consortium, smaller events and single nucleotide variants detected by NGS and large variants detected by Saphyr can be analyzed together.Recordings of all the presentations from the symposium can be found at http://bit.ly/3pLPT28About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.

ACMR – ROSEN, RESPECTED INVESTOR COUNSEL, Reminds ACM Research, Inc. Investors of Important February 19 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – ACMR

New York, New York–(Newsfile Corp. – January 18, 2021) –  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of ACM Research, Inc. (NASDAQ: ACMR) between March 6, 2019 and October 7, 2020, inclusive (the “Class Period”), of the important February 19, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for ACM investors under the federal securities laws.

To join the ACM class action, go to http://www.rosenlegal.com/cases-register-2013.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) ACM’S revenue and profits had been diverted to undisclosed related parties; (2) accordingly, ACM had materially overstated its revenues and profits; and (3) as a result, defendants’ statements about ACM’s business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 19, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-2013.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72295

info

SWBI – Is Smith & Wesson Brands, Inc. (SWBI) Stock Undervalued Right Now? (Revised)

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.

Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.

In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system’s “Value” category. Stocks with “A” grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.

One company to watch right now is Smith & Wesson Brands, Inc. (SWBI Free Report) . SWBI is currently sporting a Zacks Rank of #1 (Strong Buy), as well as an A grade for Value.

Investors should also recognize that SWBI has a P/B ratio of 5.22. The P/B ratio is used to compare a stock’s market value with its book value, which is defined as total assets minus total liabilities. Within the past 52 weeks, SWBI’s P/B has been as high as 5.55 and as low as 0.73, with a median of 2.15.

Value investors also use the P/S ratio. The P/S ratio is is calculated as price divided by sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. SWBI has a P/S ratio of 1.3. This compares to its industry’s average P/S of 1.87.

These are just a handful of the figures considered in Smith & Wesson Brands’s great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that SWBI is an impressive value stock right now.

(Note: We are reissuing this article to correct a mistake. The original article, issued on January 15, 2021, should no longer be relied upon.)

HAL – Halliburton shares continue to trade above $20 support although analysts expect weak Q4 results

Halliburton (NYSE: HAL) shares have advanced from $4.25 above $22 since March 2020, and the current price stands around $20.7. The company will publish Q4 earnings results on Tuesday, January 19th, and bad results together with renewed coronavirus concerns could add pressure on the stock price.

Fundamental analysis: Halliburton will publish Q4 earnings results on January 19th

Halliburton is one of the world’s largest oil field service companies that operate in more than 80 countries. Halliburton shares have been moving in an uptrend last several months but renewed coronavirus concerns could add pressure on the stock price.

Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today.

Vaccination is progressing slower than expected, while travel restrictions and lockdowns will keep demand for oil at low levels for a while. Halliburton could be a good long-term investment, but now is not the best time to invest in shares because it could weaken below the current price levels in the upcoming weeks.

Halliburton will publish Q4 earnings results on Tuesday, January 19th, before the market open. According to analysts, the EPS estimate stands around $0.14 (-56.3% Y/Y), while the consensus revenue estimate stands at $3.21B (-38.2% Y/Y).

We can’t still be sure when we can see a gradual return to pre-COVID oil demand levels, but once the situation has stabilized, this stock price will be at much higher levels. Last month, the company announced that it would reduce the number of employees as coronavirus continues to depress demand for oilfield services and equipment.

Positive information is that the company deployed several days ago the industry’s first electric grid-powered fracturing operation.

“Electric fracturing aligns with our goal to provide the industry with lower-carbon intensive solutions and our commitment to a sustainable energy future. With Halliburton’s leading electric fracturing capabilities, coupled with an innovative operator like Cimarex, grid power can offer one of the most effective and capital-efficient solutions for electric fracturing,” said Michael Segura, vice president of Production Enhancement for Halliburton.

Halliburton has a good position in the market, and the company will benefit once the situation with the covid pandemic stabilizes.

Technical analysis: Halliburton shares remain in a bull market, but correction could be around the corner

There are some apparent risks when it comes to investing in Halliburton shares currently, but this company will always attract potential investors and traders.

Data source: tradingview.com

When we look at the chart above, we can see that this stock price has advanced from $4.25 above $22, and as long the price is above this trend line, Halliburton shares remain in a bull market. If the price falls on the trend line and if we get a “bullish” confirmation candle, it would be an excellent entry point for short-term traders who are trading with “stop-loss” and “take profit” orders.

If the price jumps above $22, it would be a signal to trade shares, and the next price target could be around $24.

Summary

Halliburton could be a good long-term investment, but now is not the best moment to invest in shares because it could weaken below the current price levels in the upcoming weeks. The covid pandemic impacts the company’s business, but Halliburton’s fundamentals remain stable, and the company will probably not face cash flow problems. Halliburton shares remain in a bull market, but if the price falls below the $20 support level, the next target could be around $18.